Bold Science, Bold Ambition: Shaping the Future of Oncology at Ipsen

Ivan Diaz-Padilla, Senior Vice President and Global Head, Oncology Therapeutic Area Unit, R&D at Ipsen, shares his vision for building a balanced and sustainable pipeline powered by bold science.

It is a pivotal moment in Ipsen’s oncology journey, advancing our clinical-stage pipeline with bold science and a clear purpose – to bring meaningful innovation to the patients who need it most, transforming what patients and healthcare systems can expect from cancer treatment.

Across the industry, progress is accelerating, with new modalities including antibody-drug conjugates (ADCs), multi-specific antibodies, novel targeted treatments and vaccines – all redefining standards of precision and efficacy. Setting the bar at transformative care is not without its challenges, particularly in our areas of focus where innovation is scarce and options are limited.  

We believe bold science must be matched by bold execution. Our oncology pipeline is expanding with purpose, with deepening focus in immuno-oncology, building on our existing expertise and offering powerful potential for future innovation. Recognizing the promise of early science, we have advanced both an ADC and T-cell activator to Phase I trials, as well as progressing an innovative monoclonal antibody technology to reach Phase IIb/III trials. These milestones exemplify our efforts to advance care across stages of development in both solid tumors and hematological cancers, channeling and accelerating potential not where it is easiest, but where there is the greatest need.   

By combining deep expertise with a culture that embraces possibility, we are advancing therapies that challenge the status quo and aim to deliver meaningful impact for patients and their families.

It is a privilege to lead Ipsen’s oncology team into the future, where every step forward brings us closer to transforming outcomes for people living with cancer.